The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis

被引:0
|
作者
Engel, LS
Callegan, MC
Hill, JM
Folkens, AT
Shimomura, Y
OCallaghan, RJ
机构
[1] LOUISIANA STATE UNIV,CTR EYE,NEW ORLEANS,LA 70112
[2] LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT MICROBIOL IMMUNOL & PARASITOL,NEW ORLEANS,LA 70112
[3] ALCON LABS INC,FT WORTH,TX 76101
[4] OSAKA UNIV,SCH MED,DEPT OPHTHALMOL,SUITA,OSAKA 565,JAPAN
关键词
Ciloxan(R); ciprofloxacin-PSS; keratitis Pseudomonas; rabbits; Staphylococcus;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity. A commercially available form of ciprofloxacin contains benzalkonium chloride (BAC) (0.006%) and EDTA (0.05%) as preservatives. Since BAG has been shown to cause adverse changes in corneal epithelial cells, a formulation of ciprofloxacin devoid of BAC and EDTA but with the same effectiveness would be valuable. We present here the results of experiments designed to assess the efficacy of a BAC-free and EDTA-free formulation of ciprofloxacin, Ciprofloxacin-polystyrene sulfonate (PSS), in experimental models of Pseudomonas aeruginosa and Staphylococcus aureas keratitis, Both formulations of ciprofloxacin sterilized corneas infected with P aeruginosa, and both formulations showed equal bactericidal activity for S aureus, Normal eyes treated with either formulation showed mild conjunctival irritation compared to untreated normal eyes. The bactericidal activities of both formulations of ciprofloxacin were excellent, Therefore, the Ciprofloxacin-PSS formulation could serve as an effective single drug therapy for ocular infections.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [41] ROLE OF MUCIN ON EXPERIMENTAL PSEUDOMONAS KERATITIS IN RABBITS
    MITSUI, Y
    MATSUMURA, K
    KONDO, C
    TAKASHIMA, R
    INVESTIGATIVE OPHTHALMOLOGY, 1976, 15 (03): : 208 - 210
  • [42] COMPARISON OF THERAPEUTIC ROUTES IN EXPERIMENTAL PSEUDOMONAS KERATITIS
    DAVIS, SD
    SARFF, LD
    HYNDIUK, RA
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1979, 87 (05) : 710 - 716
  • [43] Efficacy of polyhexamethylene biguanide in experimental Pseudomonas keratitis
    Liu, NH
    Chung, SK
    Drake, J
    Hwang, DG
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 2416 - 2416
  • [44] EXPERIMENTAL PSEUDOMONAS KERATITIS IN IMMUNOSUPPRESSED HYBRID MICE
    HAZLETT, LD
    ROSEN, DD
    BERK, RS
    OPHTHALMIC RESEARCH, 1977, 9 (06) : 374 - 380
  • [45] Accumulation of 99mTc-ciprofloxacin in Staphylococcus aureus and Pseudomonas aeruginosa
    Sierra, J. M.
    Rodriguez-Puig, D.
    Soriano, A.
    Mensa, J.
    Piera, C.
    Vila, J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) : 2691 - 2692
  • [46] The effectiveness of fluoroquinolone antibiotics administered prophylactically for Staphylococcus aureus keratitis
    Dajcs, JJ
    Thibodeaux, BA
    Girgis, DO
    Traidej, M
    O'Callaghan, RJ
    Stroman, DW
    Schlech, BA
    Carreras, N
    Vallet, JA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U351 - U351
  • [47] Staphylococcus model of keratitis used to compare the effectiveness of three fluoroquinolones
    Moreau, JM
    Green, LC
    Engel, LS
    Abshire, RL
    Hill, JM
    OCallaghan, RJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 4072 - 4072
  • [48] SUCCESSFUL TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS KERATITIS WITH TOPICAL CIPROFLOXACIN
    INSLER, MS
    FISH, LA
    SILBERNAGEL, J
    HOBDEN, JA
    OCALLAGHAN, RJ
    HILL, JM
    OPHTHALMOLOGY, 1991, 98 (11) : 1690 - 1692
  • [49] Corneal virulence of Staphylococcus aureus in an experimental model of keratitis
    Dajcs, JJ
    Thibodeaux, BA
    Girgis, DO
    O'Callaghan, RJ
    DNA AND CELL BIOLOGY, 2002, 21 (5-6) : 375 - 382
  • [50] Efficacy of Gemifloxacin for the Treatment of Experimental Staphylococcus aureus Keratitis
    Wu, Xianggen
    Jiang, Haoran
    Xu, Yuanyuan
    Yue, Wenjie
    Yang, Lingling
    Song, Zicheng
    Chen, Hao
    Liu, Ting
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2012, 28 (04) : 420 - 427